Santhera Pharmaceuticals Holding AGSanthera Pharmaceuticals Holding AGSanthera Pharmaceuticals Holding AG

Santhera Pharmaceuticals Holding AG

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪186.15 M‬CHF
−3.44CHF
‪−41.97 M‬CHF
‪39.12 M‬CHF
‪10.08 M‬
Beta (1Y)
1.31
Employees (FY)
78
Change (1Y)
+34 +77.27%
Revenue / Employee (1Y)
‪498.31 K‬CHF
Net income / Employee (1Y)
‪−534.70 K‬CHF

About Santhera Pharmaceuticals Holding AG


CEO
Dario Eklund
Headquarters
Pratteln
Founded
1998
ISIN
CH1276028821
FIGI
BBG000QPCJ73
Santhera Pharmaceuticals Holding AG engages in the development and commercialization of products for the treatment of neuromuscular and pulmonary diseases. Its product pipeline includes Vamorolone and Lonodelestat. The company was founded by Thomas Meier in 1998 and is headquartered in Pratteln, Switzerland.

Check out other big names from the same industry as SANN.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of SANN is 14.36 CHF — it has increased by 1.25% in the past 24 hours. Watch Santhera Pharmaceuticals Holding AG stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on SIX exchange Santhera Pharmaceuticals Holding AG stocks are traded under the ticker SANN.
SANN stock has risen by 7.86% compared to the previous week, the month change is a 10.49% rise, over the last year Santhera Pharmaceuticals Holding AG has showed a 54.08% increase.
We've gathered analysts' opinions on Santhera Pharmaceuticals Holding AG future price: according to them, SANN price has a max estimate of 30.00 CHF and a min estimate of 24.00 CHF. Watch SANN chart and read a more detailed Santhera Pharmaceuticals Holding AG stock forecast: see what analysts think of Santhera Pharmaceuticals Holding AG and suggest that you do with its stocks.
SANN reached its all-time high on Sep 21, 2015 with the price of 1,389.00 CHF, and its all-time low was 5.00 CHF and was reached on Dec 2, 2022. View more price dynamics on SANN chart.
See other stocks reaching their highest and lowest prices.
SANN stock is 2.80% volatile and has beta coefficient of 1.31. Track Santhera Pharmaceuticals Holding AG stock price on the chart and check out the list of the most volatile stocks — is Santhera Pharmaceuticals Holding AG there?
Today Santhera Pharmaceuticals Holding AG has the market capitalization of ‪186.15 M‬, it has decreased by −0.44% over the last week.
Yes, you can track Santhera Pharmaceuticals Holding AG financials in yearly and quarterly reports right on TradingView.
Santhera Pharmaceuticals Holding AG is going to release the next earnings report on Apr 23, 2026. Keep track of upcoming events with our Earnings Calendar.
Santhera Pharmaceuticals Holding AG revenue for the last half-year amounts to ‪25.00 M‬ CHF, despite the estimated figure of ‪25.00 M‬ CHF. In the next half-year revenue is expected to reach ‪21.10 M‬ CHF.
SANN net income for the last half-year is ‪−26.71 M‬ CHF, while the previous report showed ‪−15.26 M‬ CHF of net income which accounts for −75.00% change. Track more Santhera Pharmaceuticals Holding AG financial stats to get the full picture.
No, SANN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 11, 2025, the company has 78 employees. See our rating of the largest employees — is Santhera Pharmaceuticals Holding AG on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Santhera Pharmaceuticals Holding AG EBITDA is ‪−27.73 M‬ CHF, and current EBITDA margin is −70.90%. See more stats in Santhera Pharmaceuticals Holding AG financial statements.
Like other stocks, SANN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Santhera Pharmaceuticals Holding AG stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Santhera Pharmaceuticals Holding AG technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Santhera Pharmaceuticals Holding AG stock shows the neutral signal. See more of Santhera Pharmaceuticals Holding AG technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.